| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
The primary target of BCR-ABL-IN-7 is the ABL kinase, including both the wild-type and the imatinib-resistant T315I gatekeeper mutant. By inhibiting ABL kinase, it blocks the downstream signaling pathways that promote the proliferation and survival of CML cells. This makes it a valuable tool for studying CML and for developing therapies to overcome imatinib resistance.
|
|---|---|
| ln Vitro |
In vitro, BCR-ABL-IN-7 effectively inhibits the activities of WT and T315I mutant ABL kinases. Its inhibitory activity is typically assessed using kinase assays that measure the phosphorylation of a substrate in the presence of the compound. These in vitro studies confirm its potential as a therapeutic agent for CML, including imatinib-resistant cases.
|
| ln Vivo |
In vivo activity of BCR-ABL-IN-7 has been studied in animal models of CML. It has been shown to inhibit tumor growth in xenograft models by blocking ABL kinase signaling. These studies provide evidence for its therapeutic potential in CML.
|
| Enzyme Assay |
Cell-free assays for BCR-ABL-IN-7 typically involve measuring its inhibitory activity against WT and T315I mutant ABL kinases using a biochemical kinase assay. The compound's IC50 values are determined by measuring the phosphorylation of a peptide substrate in the presence of varying concentrations of the compound. These assays are used to characterize the compound's potency and selectivity against ABL kinases.
|
| Cell Assay |
In vitro cellular assays are conducted to evaluate the functional activity of BCR-ABL-IN-7. CML cell lines, such as K562 cells, are treated with the compound, and cell proliferation is measured to assess its anti-proliferative activity. ABL phosphorylation is measured to assess the inhibition of ABL kinase signaling. These assays confirm that BCR-ABL-IN-7 effectively blocks ABL-mediated cellular responses.
|
| Animal Protocol |
In vivo animal experiments typically involve xenograft models of CML. Animals are administered the compound via oral gavage or injection. Tumor growth is monitored over time to assess efficacy. These studies provide evidence for the compound's anti-tumor activity.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of BCR-ABL-IN-7 are typical of a small molecule kinase inhibitor. It is a synthetic, low-molecular-weight compound. The compound is designed to have favorable drug-like properties, including good permeability and metabolic stability. Pharmacokinetic studies in animal models involve measuring plasma concentrations of the compound over time to determine its half-life, clearance, and volume of distribution.
|
| Toxicity/Toxicokinetics |
The toxicity profile of BCR-ABL-IN-7 is not extensively documented, but it is likely to be similar to other ABL kinase inhibitors. Common adverse effects may include myelosuppression, fatigue, and gastrointestinal disturbances. In preclinical studies, the compound has been shown to be well-tolerated at therapeutic doses, with a safety profile that supports its use in research.
|
| References | |
| Additional Infomation |
BCR-ABL-IN-7 is a research compound used to study CML and to develop therapies to overcome imatinib resistance. It is a potent inhibitor of both wild-type and T315I mutant ABL kinases. The compound is not approved for therapeutic use and is intended for research purposes only.
|
| Molecular Formula |
C19H16FN3O3S
|
|---|---|
| Molecular Weight |
385.412046432495
|
| Exact Mass |
385.089
|
| CAS # |
688050-42-2
|
| PubChem CID |
15988825
|
| Appearance |
White to off-white solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
572
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C2=CC=C(F)C=C2)=CC(C(NC2SC3CCCCC=3C=2C(N)=O)=O)=N1
|
| InChi Key |
ROZYTPXUZIIHHA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H16FN3O3S/c20-11-7-5-10(6-8-11)14-9-13(23-26-14)18(25)22-19-16(17(21)24)12-3-1-2-4-15(12)27-19/h5-9H,1-4H2,(H2,21,24)(H,22,25)
|
| Chemical Name |
N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(4-fluorophenyl)-1,2-oxazole-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5946 mL | 12.9732 mL | 25.9464 mL | |
| 5 mM | 0.5189 mL | 2.5946 mL | 5.1893 mL | |
| 10 mM | 0.2595 mL | 1.2973 mL | 2.5946 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
